Table 4.
Demographic and biological characteristics of SSc patients at baseline and 2-year follow-up.
| Baseline SSc (n = 28) | 2-Year follow-up SSc (n = 28) | |
|---|---|---|
| Age, yrs | 57 ± 12 | 59 ± 12 |
| Gender (M/F) | 22/6 | 22/6 |
| BMI, kg/m2 | 24 ± 4 | 24 ± 4 |
| Smokers (NS/ES/S) | 14/10/5 | 14/10/5 |
| Paq-year | 0 (0–26) | 1 (0–26) |
| FEV1 post-BD, %pred | 100 ± 20 | 98 ± 19 |
| FVC post-BD, %pred | 103 ± 20 | 101 ± 18 |
| TLC %pred | 95 ± 16 | 94 ± 13 |
| DLCO %pred | 66 ± 17 | 65 ± 13 |
| KCO %pred | 81 ± 14 | 73 ± 12*** |
| ILD yes/no | 8/20 | 11/17 |
| IT yes/no | 10/18 | 10/18 |
| OCS yes/no | 5/23 | 5/23 |
Data are expressed as mean (SD). DLCO diffusion lung capacity for CO, FEV1 forced expired volume in 1 s, FS former smoker, FVC forced vital capacity, ILD interstitial lung disease, IT immunosuppressive therapy (Mycophenolate Mofetil, methotrexate, cyclophosphamide), KCO the carbon monoxide transfer coefficient, NS non smoker, OCS oral corticosteroid, S smoker, SSc systemic sclerosis, TLC total lung capacity.
***p < 0.001 compared to Baseline.